The group highlights its ambitions in cancer again, but is at least two years away from launching a new product.
The group is taking a subcutaneous formulation of efgartigimod to regulators, but is keeping quiet about price.
Armed with the first approval for an FcRn antagonist, the Belgian company’s chief executive remains convinced by a solo strategy.
Kodiak, Biomarin and Argenx prepare for clinical catalysts.
Important breast cancer data will come in the opening months of 2022, and Glaxo and Pfizer are due pivotal RSV results.
Deals will come into even greater focus after the failure of ligelizumab, one of the group’s brightest pipeline hopes.
Quell should soon join Sangamo in the clinic, while a number of engineered Treg players are at the preclinical stage.
2021 rounds off with key FDA decisions for Argenx, Calliditas and Merck, while Novartis will be hoping for an early Leqvio verdict.